NDAINJECTIONINJECTABLE
Approved
Dec 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Drug data last refreshed 16h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPTIMARK (gadoversetamide) is a gadolinium-based contrast agent administered by injection for magnetic resonance imaging (MRI) enhancement. It works by accumulating in tissues and altering local magnetic field properties to improve MRI image contrast and visualization. This product is used across diagnostic imaging to enhance visualization of lesions and abnormalities in the brain, spine, and body.
LOE Approaching
With LOE approaching and moderate competitive pressure (30), this product faces contraction; brand teams should prepare for transition to mature/post-LOE management with reduced headcount and repositioning efforts.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK Injection
Started Feb 2009
0Nephrogenic Systemic FibrosisRenal Insufficiency
Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark (Gadoversetamide) in Pediatric Patients
Started May 2002
100 enrolled
Pathological Processes
Career Relevance
OPTIMARK offers limited career growth opportunities, with zero currently linked positions reflecting its mature, commoditized market status and approaching loss of exclusivity. Roles on this product focus on defensive commercial strategy, cost management, and diagnostic imaging market expertise rather than innovation or expansion.
Worked on OPTIMARK at Guerbet? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.